Albireo Pharma Inc (ALBO) Gets a Buy Rating from Needham


Needham analyst Alan Carr maintained a Buy rating on Albireo Pharma Inc (ALBO) on August 8 and set a price target of $50. The company’s shares closed on Friday at $22.86.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.8% and a 41.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Albireo Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $55, implying a 140.6% upside from current levels. In a report issued on August 9, Wedbush also maintained a Buy rating on the stock with a $69 price target.

See today’s analyst top recommended stocks >>

Based on Albireo Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.63 million. In comparison, last year the company had a GAAP net loss of $14.6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts